

Drug Discovery Services - Company Evaluation Report, 2025

<https://marketpublishers.com/r/DF75F5EC1F7BEN.html>

Date: August 2025

Pages: 155

Price: US\$ 2,650.00 (Single User License)

ID: DF75F5EC1F7BEN

Abstracts

The Drug Discovery Services Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Drug Discovery Services. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 150 companies, of which the Top 25 Drug Discovery Services Companies were categorized and recognized as the quadrant leaders.

Contract Research Organizations (CROs) provide a wide range of drug discovery services, including hit identification, medicinal chemistry, and hit-to-lead optimization. The growth of the drug discovery services market is primarily driven by increasing R&D investments from pharmaceutical and biopharmaceutical companies, coupled with the expanding drug development pipeline, which has led to a greater need for outsourced analytical testing. Additional growth drivers include rising research initiatives for rare diseases and orphan drugs, as well as the high costs associated with in-house drug development. Furthermore, advancements in technology, the emergence of innovative drug discovery methods, the expiration of key drug patents, and the growing demand for specialized testing services among end users are creating new opportunities for market players.

The 360 Quadrant maps the Drug Discovery Services companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Drug Discovery Services quadrant. The top criteria for product footprint evaluation included process (target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation) type (chemistry services and biology services) drug type (small molecules and biologics) therapeutic area

(oncology, infectious diseases, neurological diseases, immunological diseases, endocrine and metabolic diseases, respiratory diseases, digestive system diseases, cardiovascular diseases, genitourinary diseases and women's health, and other therapeutic areas) end user (pharmaceutical & biotechnology companies, academic institutes, and other end users).

Key Players:

Some of the prominent players are Labcorp (US), Eurofins Scientific (Germany), Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), Evotec (Germany), WuXi AppTec (China), Syngene International Limited (India), Curia Global Inc. (US), Dr. Reddy Laboratories Ltd. (Aurigene Pharmaceutical Services Ltd.) (India), Pharmaron (China), and Piramal Enterprises Ltd. (India) and others. These players are increasingly focusing on product launches and enhancements, investments, partnerships, collaborations, joint ventures, funding, acquisitions, expansions, agreements, sales contracts, and alliances to strengthen their presence in the global market.

Top 3 Companies

LabCorp

LabCorp is a leading healthcare diagnostics company that delivers a broad range of clinical laboratory services and comprehensive drug development support. It serves a diverse client base, including hospitals, managed care organizations, and pharmaceutical and biotechnology firms. The company operates through two main segments: LabCorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The Dx segment functions as an independent clinical laboratory network, encompassing approximately 2,000 patient service centers across the U.S. The BLS segment supports the drug discovery and development pipeline, offering both early-phase and late-phase services. These include lead optimization, in vivo pharmacology, toxicology studies, and disease modeling for pharmaceutical, biopharmaceutical, and medical device companies. LabCorp is also a key provider of laboratory testing for the chemical and agrochemical industries and is recognized as a market leader in toxicology, central laboratory services, and discovery research.

Evotec

Evotec is a globally recognized drug discovery and development partner, collaborating with pharmaceutical and biotechnology companies, academic institutions, patient

advocacy groups, and venture capital firms. The company offers a comprehensive suite of drug discovery services through fee-for-service projects, integrated discovery alliances, development partnerships, licensing agreements, and strategic consulting. Evotec operates through two core segments: EVT Execute and EVT Innovate. Both segments contribute to the company's drug discovery offerings. EVT Execute focuses on scalable and high-quality drug discovery services, while EVT Innovate is centered on building and advancing innovative therapeutic projects through strategic partnerships and internal pipeline development.

Selvita

Selvita is a drug discovery company that provides a wide range of research and development services to support pharmaceutical innovation. Its capabilities span medicinal chemistry, process research, preclinical studies, ADME/DMPK, protein chemistry, analytical and industrial chemistry, and bioinformatics. The company also conducts comparative studies for biosimilars and undertakes integrated drug discovery projects, enabling clients to access end-to-end solutions tailored to their drug development needs.

Contents

1 INTRODUCTION

1.1 MARKET DEFINITION

1.2 STAKEHOLDERS

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW

3.1 INTRODUCTION

3.2 MARKET DYNAMICS

3.2.1 DRIVERS

3.2.1.1 Booming research & development expenditure in pharma-biotech sector

3.2.1.2 Growing pipeline of pharmaceutical and biopharmaceutical companies

3.2.1.3 Rising research on rare diseases and orphan drugs

3.2.1.4 Increasing reliance on outsourcing due to costly in-house drug development

3.2.2 RESTRAINTS

3.2.2.1 Stringent regulations

3.2.3 OPPORTUNITIES

3.2.3.1 Technological advancements and new drug discovery techniques

3.2.3.2 Rising demand for specialized testing services

3.2.3.3 Patent expiry of key biologics

3.2.3.4 High growth prospects in emerging markets

3.2.4 CHALLENGES

3.2.4.1 Economic uncertainties worldwide

3.2.5 MARKET TRENDS

3.2.5.1 Adoption of AI in drug discovery

3.2.5.2 Increased outsourcing in emerging economies

3.2.5.3 Consolidation of contract research organizations

3.2.5.4 Integrated end-to-end R&D service offerings

3.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

3.4 SUPPLY CHAIN ANALYSIS

3.5 VALUE CHAIN ANALYSIS

3.6 ECOSYSTEM ANALYSIS

3.7 TECHNOLOGY ANALYSIS

3.7.1 KEY TECHNOLOGIES

3.7.1.1 High-throughput screening

3.7.1.2 CRISPR gene editing

3.7.1.3 Structure-based drug design/Computer-aided drug design

3.7.2 COMPLEMENTARY TECHNOLOGIES

3.7.2.1 Automated liquid handling

3.7.2.2 In silico modeling

3.7.2.3 Patient-derived xenografts and organoids

3.7.3 ADJACENT TECHNOLOGIES

3.7.3.1 Nanotechnology

3.7.3.2 Synthetic biology

3.7.3.3 Organ-on-a-chip technology

3.8 PATENT ANALYSIS

3.9 KEY CONFERENCES AND EVENTS, 2025–2026

3.10 PORTER'S FIVE FORCES ANALYSIS

3.10.1 BARGAINING POWER OF SUPPLIERS

3.10.2 BARGAINING POWER OF BUYERS

3.10.3 THREAT OF NEW ENTRANTS

3.10.4 THREAT OF SUBSTITUTES

3.10.5 INTENSITY OF COMPETITIVE RIVALRY

3.11 IMPACT OF AI ON DRUG DISCOVERY SERVICES MARKET

3.11.1 INTRODUCTION

3.11.2 MARKET POTENTIAL OF AI IN DRUG DISCOVERY SERVICES

3.11.3 AI USE CASES

3.11.4 FUTURE OF GENERATIVE AI IN DRUG DISCOVERY SERVICES MARKET

4 COMPETITIVE LANDSCAPE

4.1 INTRODUCTION

4.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

4.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET

4.3 REVENUE ANALYSIS, 2020?2024

4.4 MARKET SHARE ANALYSIS, 2024

4.5 COMPANY VALUATION AND FINANCIAL METRICS

4.6 BRAND/SERVICE COMPARISON

4.6.1 THERMO FISHER SCIENTIFIC INC. (US)

4.6.2 CHARLES RIVER LABORATORIES (US)

- 4.6.3 LABCORP (US)
- 4.6.4 WUXI APPTTEC (CHINA)
- 4.6.5 PHARMARON (CHINA)
- 4.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
 - 4.7.1 STARS
 - 4.7.2 EMERGING LEADERS
 - 4.7.3 PERVASIVE PLAYERS
 - 4.7.4 PARTICIPANTS
 - 4.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
 - 4.7.5.1 Company footprint
 - 4.7.5.2 Region footprint
 - 4.7.5.3 Process footprint
 - 4.7.5.4 Type footprint
 - 4.7.5.5 Therapeutic area footprint
 - 4.7.5.6 Drug type footprint
- 4.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
 - 4.8.1 PROGRESSIVE COMPANIES
 - 4.8.2 RESPONSIVE COMPANIES
 - 4.8.3 DYNAMIC COMPANIES
 - 4.8.4 STARTING BLOCKS
 - 4.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
 - 4.8.5.1 Detailed list of key startups/SMEs
 - 4.8.5.2 Competitive benchmarking of key startups/SMEs
- 4.9 COMPETITIVE SCENARIO
 - 4.9.1 SERVICE LAUNCHES
 - 4.9.2 DEALS
 - 4.9.3 EXPANSIONS
 - 4.9.4 OTHER DEVELOPMENTS

5 COMPANY PROFILES

- 5.1 KEY PLAYERS
 - 5.1.1 THERMO FISHER SCIENTIFIC INC.
 - 5.1.1.1 Business overview
 - 5.1.1.2 Services offered
 - 5.1.1.3 Recent developments
 - 5.1.1.3.1 Service launches
 - 5.1.1.3.2 Deals
 - 5.1.1.3.3 Expansions

- 5.1.1.4 MnM view
 - 5.1.1.4.1 Key strengths
 - 5.1.1.4.2 Strategic choices
 - 5.1.1.4.3 Weaknesses and competitive threats
- 5.1.2 CHARLES RIVER LABORATORIES
 - 5.1.2.1 Business overview
 - 5.1.2.2 Services offered
 - 5.1.2.3 Recent developments
 - 5.1.2.3.1 Service launches
 - 5.1.2.3.2 Deals
 - 5.1.2.4 MnM view
 - 5.1.2.4.1 Key strengths
 - 5.1.2.4.2 Strategic choices
 - 5.1.2.4.3 Weaknesses and competitive threats
- 5.1.3 WUXI APPTec
 - 5.1.3.1 Business overview
 - 5.1.3.2 Services offered
 - 5.1.3.3 Recent developments
 - 5.1.3.3.1 Expansions
 - 5.1.3.4 MnM view
 - 5.1.3.4.1 Key strengths
 - 5.1.3.4.2 Strategic choices
 - 5.1.3.4.3 Weaknesses and competitive threats
- 5.1.4 PHARMARON
 - 5.1.4.1 Business overview
 - 5.1.4.2 Services offered
 - 5.1.4.2.1 Deals
 - 5.1.4.3 MnM view
 - 5.1.4.3.1 Key strengths
 - 5.1.4.3.2 Strategic choices
 - 5.1.4.3.3 Weaknesses and competitive threats
- 5.1.5 LABCORP
 - 5.1.5.1 Business overview
 - 5.1.5.2 Services offered
 - 5.1.5.3 Recent developments
 - 5.1.5.3.1 Deals
 - 5.1.5.3.2 Expansions
 - 5.1.5.4 MnM view
 - 5.1.5.4.1 Key strengths

- 5.1.5.4.2 Strategic choices
- 5.1.5.4.3 Weaknesses and competitive threats
- 5.1.6 EVOTEC
 - 5.1.6.1 Business overview
 - 5.1.6.2 Services offered
 - 5.1.6.3 Recent developments
 - 5.1.6.3.1 Deals
 - 5.1.6.3.2 Expansions
 - 5.1.6.3.3 Other developments
- 5.1.7 SYNGENE INTERNATIONAL LIMITED
 - 5.1.7.1 Business overview
 - 5.1.7.2 Services offered
 - 5.1.7.3 Recent developments
 - 5.1.7.3.1 Deals
 - 5.1.7.3.2 Expansions
- 5.1.8 EUROFINS SCIENTIFIC
 - 5.1.8.1 Business overview
 - 5.1.8.2 Services offered
 - 5.1.8.3 Recent developments
 - 5.1.8.3.1 Service launches
 - 5.1.8.3.2 Deals
 - 5.1.8.3.3 Expansions
- 5.1.9 JUBILANT PHARMOVA LIMITED
 - 5.1.9.1 Business overview
 - 5.1.9.2 Services offered
 - 5.1.9.3 Recent developments
 - 5.1.9.3.1 Deals
 - 5.1.9.3.2 Expansions
- 5.1.10 GENSCRIPT
 - 5.1.10.1 Business overview
 - 5.1.10.2 Services offered
 - 5.1.10.3 Recent developments
 - 5.1.10.3.1 Service launches
 - 5.1.10.3.2 Deals
- 5.1.11 FRONTAGE HOLDINGS CORPORATION
 - 5.1.11.1 Business overview
 - 5.1.11.2 Services offered
 - 5.1.11.3 Recent developments
 - 5.1.11.3.1 Service launches

- 5.1.11.3.2 Deals
- 5.1.11.3.3 Expansions
- 5.1.12 PIRAMAL ENTERPRISES LTD.
 - 5.1.12.1 Business overview
 - 5.1.12.2 Services offered
 - 5.1.12.3 Recent developments
 - 5.1.12.3.1 Expansions
- 5.1.13 AURIGENE PHARMACEUTICAL SERVICES LTD.
 - 5.1.13.1 Business overview
 - 5.1.13.2 Services offered
 - 5.1.13.3 Recent developments
 - 5.1.13.3.1 Service launches
 - 5.1.13.3.2 Deals
 - 5.1.13.3.3 Expansions
- 5.1.14 CURIA GLOBAL, INC.
 - 5.1.14.1 Business overview
 - 5.1.14.2 Services offered
 - 5.1.14.3 Recent developments
 - 5.1.14.3.1 Service launches
 - 5.1.14.3.2 Deals
 - 5.1.14.3.3 Other developments
- 5.1.15 SHANGHAI MEDICILON INC.
 - 5.1.15.1 Business overview
 - 5.1.15.2 Services offered
 - 5.1.15.3 Recent developments
 - 5.1.15.3.1 Deals
 - 5.1.15.3.2 Expansions
- 5.1.16 SYGNATURE DISCOVERY
 - 5.1.16.1 Business overview
 - 5.1.16.2 Services offered
 - 5.1.16.2.1 Deals
 - 5.1.16.2.2 Expansions
- 5.2 OTHER PLAYERS
 - 5.2.1 SELVITA
 - 5.2.2 VIVA BIOTECH
 - 5.2.3 TCG LIFESCIENCES PVT. LTD.
 - 5.2.4 SHANGHAI CHEMPARTNER
 - 5.2.5 DOMAINEX
 - 5.2.6 NUVISAN GMBH

- 5.2.7 DALTON PHARMA SERVICES
- 5.2.8 ARAGEN LIFE SCIENCES LTD.
- 5.2.9 ONCODESIGN SERVICES

6 APPENDIX

6.1 RESEARCH METHODOLOGY

6.1.1 RESEARCH DATA

6.1.1.1 Secondary data

6.1.1.2 Primary data

6.1.2 RESEARCH ASSUMPTIONS

6.1.3 RESEARCH LIMITATIONS

6.1.4 RISK ANALYSIS

6.2 COMPANY EVALUATION MATRIX: METHODOLOGY

6.3 AUTHOR DETAILS

List Of Tables

LIST OF TABLES

TABLE 1 DRUG DISCOVERY SERVICES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS

TABLE 2 US: BIOLOGICS GOING OFF PATENT, 2025–2030

TABLE 3 DRUG DISCOVERY SERVICES MARKET: PROMINENT ACQUISITIONS, 2021–2024

TABLE 4 DRUG DISCOVERY SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM

TABLE 5 DRUG DISCOVERY SERVICES MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2021–2024

TABLE 6 DRUG DISCOVERY SERVICES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026

TABLE 7 KEY COMPANIES IMPLEMENTING AI

TABLE 8 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2021–2024

TABLE 9 DRUG DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION

TABLE 10 DRUG DISCOVERY SERVICES MARKET: REGION FOOTPRINT

TABLE 11 DRUG DISCOVERY SERVICES MARKET: PROCESS FOOTPRINT

TABLE 12 DRUG DISCOVERY SERVICES MARKET: TYPE FOOTPRINT

TABLE 13 DRUG DISCOVERY SERVICES MARKET: THERAPEUTIC AREA FOOTPRINT

TABLE 14 DRUG DISCOVERY SERVICES MARKET: DRUG TYPE FOOTPRINT

TABLE 15 DRUG DISCOVERY SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES

TABLE 16 DRUG DISCOVERY SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES

TABLE 17 DRUG DISCOVERY SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025

TABLE 18 DRUG DISCOVERY SERVICES MARKET: DEALS, JANUARY 2021–JANUARY 2025

TABLE 19 DRUG DISCOVERY SERVICES MARKET: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 20 DRUG DISCOVERY SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025

TABLE 21 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW

TABLE 22 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED

TABLE 23 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES, JANUARY

2021–JANUARY 2025

TABLE 24 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–JANUARY 2025

TABLE 25 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 26 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW

TABLE 27 CHARLES RIVER LABORATORIES: SERVICES OFFERED

TABLE 28 CHARLES RIVER LABORATORIES: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025

TABLE 29 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021–JANUARY 2025

TABLE 30 WUXI APPTEC: COMPANY OVERVIEW

TABLE 31 WUXI APPTEC: SERVICES OFFERED

TABLE 32 WUXI APPTEC: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 33 PHARMARON: COMPANY OVERVIEW

TABLE 34 PHARMARON: SERVICES OFFERED

TABLE 35 PHARMARON: DEALS, JANUARY 2021–JANUARY 2025

TABLE 36 LABCORP: COMPANY OVERVIEW

TABLE 37 LABCORP: SERVICES OFFERED

TABLE 38 LABCORP: DEALS, JANUARY 2021–JANUARY 2025

TABLE 39 LABCORP: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 40 EVOTEC: COMPANY OVERVIEW

TABLE 41 EVOTEC: SERVICES OFFERED

TABLE 42 EVOTEC: DEALS, JANUARY 2021–JANUARY 2025

TABLE 43 EVOTEC: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 44 EVOTEC: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025

TABLE 45 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW

TABLE 46 SYNGENE INTERNATIONAL LIMITED: SERVICES OFFERED

TABLE 47 SYNGENE INTERNATIONAL LIMITED: DEALS, JANUARY 2021–JANUARY 2025

TABLE 48 SYNGENE INTERNATIONAL LIMITED: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 49 EUROFINS SCIENTIFIC: COMPANY OVERVIEW

TABLE 50 EUROFINS SCIENTIFIC: SERVICES OFFERED

TABLE 51 EUROFINS SCIENTIFIC: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025

TABLE 52 EUROFINS SCIENTIFIC: DEALS, JANUARY 2021–JANUARY 2025

TABLE 53 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 54 JUBILANT PHARMOVA LIMITED: COMPANY OVERVIEW

TABLE 55 JUBILANT PHARMOVA LIMITED: SERVICES OFFERED

TABLE 56 JUBILANT PHARMOVA LIMITED: DEALS, JANUARY 2021–JANUARY 2025

TABLE 57 JUBILANT PHARMOVA LIMITED: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 58 GENSCRIPT: COMPANY OVERVIEW

TABLE 59 GENSCRIPT: SERVICES OFFERED

TABLE 60 GENSCRIPT: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025

TABLE 61 GENSCRIPT: DEALS, JANUARY 2021–JANUARY 2025

TABLE 62 FRONTAGE HOLDINGS CORPORATION: COMPANY OVERVIEW

TABLE 63 FRONTAGE HOLDINGS CORPORATION: SERVICES OFFERED

TABLE 64 FRONTAGE HOLDINGS CORPORATION: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025

TABLE 65 FRONTAGE HOLDINGS CORPORATION: DEALS, JANUARY 2021–JANUARY 2025

TABLE 66 FRONTAGE HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 67 PIRAMAL ENTERPRISES LTD.: COMPANY OVERVIEW

TABLE 68 PIRAMAL ENTERPRISES LTD.: SERVICES OFFERED

TABLE 69 PIRAMAL ENTERPRISES LTD.: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 70 DR. REDDY'S LABORATORIES LTD.: COMPANY OVERVIEW

TABLE 71 AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICES OFFERED

TABLE 72 AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025

TABLE 73 AURIGENE PHARMACEUTICAL SERVICES LTD.: DEALS, JANUARY 2021–JANUARY 2025

TABLE 74 AURIGENE PHARMACEUTICAL SERVICES LTD.: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 75 CURIA GLOBAL, INC.: COMPANY OVERVIEW

TABLE 76 CURIA GLOBAL, INC.: SERVICES OFFERED

TABLE 77 CURIA GLOBAL, INC.: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025

TABLE 78 CURIA GLOBAL, INC.: DEALS, JANUARY 2021–JANUARY 2025

TABLE 79 CURIA GLOBAL, INC.: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025

TABLE 80 SHANGHAI MEDICILON INC.: COMPANY OVERVIEW

TABLE 81 SHANGHAI MEDICILON INC.: SERVICES OFFERED

TABLE 82 SHANGHAI MEDICILON INC.: DEALS, JANUARY 2021–JANUARY 2025

TABLE 83 SHANGHAI MEDICILON INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 84 SYGNATURE DISCOVERY: COMPANY OVERVIEW

TABLE 85 SYGNATURE DISCOVERY: SERVICES OFFERED

TABLE 86 SYGNATURE DISCOVERY: DEALS, JANUARY 2021–JANUARY 2025

TABLE 87 SYGNATURE DISCOVERY: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 88 SELVITA: COMPANY OVERVIEW

TABLE 89 VIVA BIOTECH: COMPANY OVERVIEW

TABLE 90 TCG LIFESCIENCES PVT. LTD.: COMPANY OVERVIEW

TABLE 91 SHANGHAI CHEMPARTNER: COMPANY OVERVIEW

TABLE 92 DOMAINEX: COMPANY OVERVIEW

TABLE 93 NUVISAN GMBH: COMPANY OVERVIEW

TABLE 94 DALTON PHARMA SERVICES: COMPANY OVERVIEW

TABLE 95 ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW

TABLE 96 ONCODESIGN SERVICES: COMPANY OVERVIEW

TABLE 97 DRUG DISCOVERY SERVICES MARKET: RISK ANALYSIS

List Of Figures

LIST OF FIGURES

- FIGURE 1 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2025 VS. 2030 (USD MILLION)
- FIGURE 2 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
- FIGURE 3 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2025 VS. 2030 (USD MILLION)
- FIGURE 4 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030
- FIGURE 5 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
- FIGURE 6 REGIONAL SNAPSHOT OF DRUG DISCOVERY SERVICES MARKET, 2025–2030
- FIGURE 7 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
- FIGURE 8 GLOBAL PHARMACEUTICAL R&D SPENDING, 2016–2030
- FIGURE 9 ACTIVE PHARMACEUTICAL PIPELINE, 2014–2024
- FIGURE 10 NUMBER OF DRUGS GIVEN ORPHAN DRUG STATUS, 2013–2023
- FIGURE 11 AVERAGE COST OF DEVELOPING PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2013–2023 (USD BILLION)
- FIGURE 12 NEW REVENUE POCKETS FOR PLAYERS IN DRUG DISCOVERY SERVICES MARKET
- FIGURE 13 DRUG DISCOVERY SERVICES MARKET: SUPPLY CHAIN ANALYSIS
- FIGURE 14 DRUG DISCOVERY SERVICES MARKET: VALUE CHAIN ANALYSIS
- FIGURE 15 DRUG DISCOVERY SERVICES MARKET: ECOSYSTEM ANALYSIS
- FIGURE 16 DRUG DISCOVERY SERVICES MARKET: PATENT ANALYSIS, 2014–2024
- FIGURE 17 DRUG DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
- FIGURE 18 AI USE CASES
- FIGURE 19 REVENUE ANALYSIS OF KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2020?2024
- FIGURE 20 MARKET SHARE ANALYSIS OF DRUG DISCOVERY SERVICES MARKET, 2024
- FIGURE 21 RANKING OF KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2024
- FIGURE 22 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS, 2024

FIGURE 23 EV/EBITDA OF KEY PLAYERS, 2024

FIGURE 24 DRUG DISCOVERY SERVICES MARKET: BRAND/SERVICE
COMPARISON

FIGURE 25 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION
MATRIX (KEY PLAYERS), 2024

FIGURE 26 DRUG DISCOVERY SERVICES MARKET: COMPANY FOOTPRINT

FIGURE 27 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION
MATRIX (STARTUPS/SMES), 2024

FIGURE 28 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)

FIGURE 29 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2023)

FIGURE 30 WUXI APPTTEC: COMPANY SNAPSHOT (2023)

FIGURE 31 PHARMARON: COMPANY SNAPSHOT (2023)

FIGURE 32 LABCORP: COMPANY SNAPSHOT (2023)

FIGURE 33 EVOTEC: COMPANY SNAPSHOT (2023)

FIGURE 34 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2023)

FIGURE 35 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)

FIGURE 36 JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT (2023)

FIGURE 37 GENSCRIPT: COMPANY SNAPSHOT (2023)

FIGURE 38 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2023)

FIGURE 39 PIRAMAL ENTERPRISES LTD.: COMPANY SNAPSHOT (2023)

FIGURE 40 DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT (2023)

FIGURE 41 DRUG DISCOVERY SERVICES MARKET: RESEARCH DESIGN

I would like to order

Product name: Drug Discovery Services - Company Evaluation Report, 2025

Product link: <https://marketpublishers.com/r/DF75F5EC1F7BEN.html>

Price: US\$ 2,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DF75F5EC1F7BEN.html>